Newron?s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv (safinamide) for Parkinson?s disease in Canada
July 10, 2019 11:35 AM Eastern Daylight Time
MILAN & MONTREAL--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (?Newron?) (SIX: NWRN, XETRA: NP5.XE), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, is pleased to report that its partner Zambon S.p.A. and Valeo Pharma Inc. announced today the launch of Onstryv? (safinamide) for the treatment of Parkinson?s disease in Canada.
?This marks another key milestone for Newron and its commercial partners in providing availability of safinamide in Canada for the treatment of patients suffering from Parkinson?s disease,? commented Newron CEO Stefan Weber. ?Now, with the Canadian launch, safinamide is available across the North American region.?
The full text of the announcement from Zambon S.p.A and Valeo Pharma Inc. is as follows:
Valeo Pharma Announces the Canadian Launch of Onstryv? (Safinamide Tablets) for the Treatment of Parkinson?s Disease
- First new oral treatment for Parkinson?s Disease approved in over a decade
- Parkinson?s Disease affects a growing number of Canadians with over 100,000 currently afflicted
- Total Canadian market for Parkinson?s Disease drugs exceeds $100 million per year